Bausch + Lomb Corporation (BLCO)
undefined
undefined%
At close: undefined
18.60
0.03%
After-hours Dec 13, 2024, 04:10 PM EST

Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide.

It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.

The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.

The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use.

The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices.

The company was founded in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corporation
Bausch + Lomb Corporation logo
Country CA
IPO Date May 6, 2022
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 13,000
CEO Brenton L. Saunders J.D.

Contact Details

Address:
520 Applewood Crescent
Vaughan, ON
CA
Website https://www.bausch.com

Stock Details

Ticker Symbol BLCO
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860742
CUSIP Number 071705107
ISIN Number CA0717051076
Employer ID 00-0000000
SIC Code 3851

Key Executives

Name Position
Brenton L. Saunders J.D. Chief Executive Officer & Chairman
Osama A. Eldessouky Executive Vice President & Chief Financial Officer
Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain & Operations Officer
Andrew Stewart President of Global Pharmaceuticals & International Consumer
Asli Gevgilili Executive Vice President & Chief Human Resources Officer
Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development & Digital Officer
Dr. Yehia Hashad M.D. Executive Vice President of Research & Development and Chief Medical officer
Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer
Jonathon L. Kellerman Chief Compliance Officer
T.J. Crawford Chief Communications Officer

Latest SEC Filings

Date Type Title
Nov 01, 2024 8-K Current Report
Oct 30, 2024 10-Q Quarterly Report
Oct 30, 2024 8-K Current Report
Oct 04, 2024 4/A [Amend] Filing
Oct 04, 2024 4/A [Amend] Filing
Oct 01, 2024 4 Filing
Oct 01, 2024 4 Filing
Aug 07, 2024 4 Filing
Aug 06, 2024 4 Filing
Aug 06, 2024 4 Filing